JPWO2022225006A1 - - Google Patents
Info
- Publication number
- JPWO2022225006A1 JPWO2022225006A1 JP2023515511A JP2023515511A JPWO2022225006A1 JP WO2022225006 A1 JPWO2022225006 A1 JP WO2022225006A1 JP 2023515511 A JP2023515511 A JP 2023515511A JP 2023515511 A JP2023515511 A JP 2023515511A JP WO2022225006 A1 JPWO2022225006 A1 JP WO2022225006A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021072201 | 2021-04-21 | ||
| PCT/JP2022/018413 WO2022225006A1 (ja) | 2021-04-21 | 2022-04-21 | β線を放出する核種で標識されたヒト化抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2022225006A1 true JPWO2022225006A1 (https=) | 2022-10-27 |
Family
ID=83722332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515511A Pending JPWO2022225006A1 (https=) | 2021-04-21 | 2022-04-21 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240189461A1 (https=) |
| EP (1) | EP4328244A4 (https=) |
| JP (1) | JPWO2022225006A1 (https=) |
| KR (1) | KR20230174243A (https=) |
| CN (1) | CN117377696A (https=) |
| CA (1) | CA3217638A1 (https=) |
| TW (1) | TW202308698A (https=) |
| WO (1) | WO2022225006A1 (https=) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013157102A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| JP2016504370A (ja) * | 2012-12-28 | 2016-02-12 | プレシジョン・バイオロジクス・インコーポレイテッド | 結腸癌及び膵臓癌の診断ならびに治療のための、ヒト化モノクローナル抗体及び使用方法 |
| JP2017503763A (ja) * | 2013-12-03 | 2017-02-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｃｃ発現細胞を撮像するための化合物及び組成物 |
| WO2017217347A1 (ja) * | 2016-06-13 | 2017-12-21 | 国立大学法人鹿児島大学 | ＩｇＧ結合ペプチドによる部位特異的ＲＩ標識抗体 |
| JP2021506842A (ja) * | 2017-12-18 | 2021-02-22 | ヤンセン バイオテツク，インコーポレーテツド | ポリペプチドの放射性標識 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07203974A (ja) | 1994-01-13 | 1995-08-08 | Tosoh Corp | 癌特異的ムチンを認識する抗体の遺伝子断片等 |
| JPH115749A (ja) | 1997-06-13 | 1999-01-12 | Tosoh Corp | 癌治療医薬品組成物 |
| SE0200943D0 (sv) | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
| US20170137534A1 (en) * | 2002-06-14 | 2017-05-18 | Immunomedics, Inc. | Anti-Pancreatic Cancer Antibodies |
| WO2011118699A1 (ja) | 2010-03-24 | 2011-09-29 | 株式会社カネカ | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
| WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| CA2948013A1 (en) * | 2014-06-30 | 2016-01-07 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2) |
| ES3058443T3 (es) | 2015-05-20 | 2026-03-10 | Univ Kagoshima | Modificación específica de anticuerpo con péptido de unión a IgG |
| JP7291395B2 (ja) | 2017-06-16 | 2023-06-15 | 国立大学法人 鹿児島大学 | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| AU2019302659B2 (en) * | 2018-07-13 | 2026-04-16 | Memorial Sloan Kettering Cancer Center | N-acetylgalactosamino dendron-clearing agent for DOTA-pretargeted radioimmunotherapy |
| IL292133A (en) * | 2019-10-18 | 2022-06-01 | Nihon Mediphysics Co Ltd | Ri-labeled humanized antibody |
| JP2021072201A (ja) | 2019-10-30 | 2021-05-06 | 東芝ライテック株式会社 | ヒータ |
-
2022
- 2022-04-21 KR KR1020237039584A patent/KR20230174243A/ko active Pending
- 2022-04-21 JP JP2023515511A patent/JPWO2022225006A1/ja active Pending
- 2022-04-21 EP EP22791777.0A patent/EP4328244A4/en active Pending
- 2022-04-21 CN CN202280030059.8A patent/CN117377696A/zh active Pending
- 2022-04-21 CA CA3217638A patent/CA3217638A1/en active Pending
- 2022-04-21 WO PCT/JP2022/018413 patent/WO2022225006A1/ja not_active Ceased
- 2022-04-21 TW TW111115273A patent/TW202308698A/zh unknown
- 2022-04-21 US US18/556,582 patent/US20240189461A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013157102A1 (ja) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| JP2016504370A (ja) * | 2012-12-28 | 2016-02-12 | プレシジョン・バイオロジクス・インコーポレイテッド | 結腸癌及び膵臓癌の診断ならびに治療のための、ヒト化モノクローナル抗体及び使用方法 |
| JP2017503763A (ja) * | 2013-12-03 | 2017-02-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｃｃ発現細胞を撮像するための化合物及び組成物 |
| WO2017217347A1 (ja) * | 2016-06-13 | 2017-12-21 | 国立大学法人鹿児島大学 | ＩｇＧ結合ペプチドによる部位特異的ＲＩ標識抗体 |
| JP2021506842A (ja) * | 2017-12-18 | 2021-02-22 | ヤンセン バイオテツク，インコーポレーテツド | ポリペプチドの放射性標識 |
Non-Patent Citations (1)
| Title |
|---|
| 遠藤啓吾，渡辺直行: "ＲＩ標識モノクローナル抗体を用いた放射免疫診断の方法論とその臨床的有用性", 日本臨牀, vol. 54, no. 6, JPN6022020667, 1 June 1996 (1996-06-01), pages 138 - 143, ISSN: 0005787537 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202308698A (zh) | 2023-03-01 |
| EP4328244A1 (en) | 2024-02-28 |
| US20240189461A1 (en) | 2024-06-13 |
| EP4328244A4 (en) | 2026-04-01 |
| CA3217638A1 (en) | 2022-10-27 |
| CN117377696A (zh) | 2024-01-09 |
| KR20230174243A (ko) | 2023-12-27 |
| WO2022225006A1 (ja) | 2022-10-27 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250408 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260203 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260319 |